Adela Partners with Dendi to Commercialize Innovative Cancer Detection Platform

Dendi’s laboratory information system will support Adela in effectively delivering its MRD clinical diagnostics test to patients and providers.

Durham, NC, (March 17, 2025) — Adela, an innovator in blood testing for early cancer detection, has chosen Dendi to extend its genome-wide methylome enrichment technology to clinical applications. This collaboration aims to enhance cancer management and treatment decisions, aligning with Adela’s mission to harness the power of genomics to deliver accessible diagnostics and improve patient care.

Adela’s proprietary platform captures the methylation patterns across the cancer genome without decoding the entire DNA sequence, aiming to make its methods more cost-effective for wider screening. This approach enables the detection of tumor DNA fragments in the bloodstream, which can be traced back to their origins by analyzing methylation patterns.

In September 2024, Adela announced successful clinical validation of its Minimal Residual Disease (MRD) test for predicting and monitoring recurrence in head and neck cancer patients, regardless of HPV status. The test identified recurrences up to 14.9 months earlier than standard clinical examinations and imaging.

To support Adela’s diagnostic services, Dendi will implement a suite of tailored solutions:

• Integrations for Next-Generation Sequencing (NGS) Pipeline: Seamless integration with Adela’s NGS workflows to ensure efficient data processing and analysis.
• APIs for Data Reconciliation: Robust APIs to facilitate accurate and efficient data reconciliation across various platforms.
• Secure Login Authentication: Enhanced security measures to protect sensitive patient data and ensure compliance with regulatory standards.
• Custom Report Template Creation with Advanced Data Visualization: Development of bespoke report templates featuring Adela’s branding and sophisticated data visualization to effectively communicate complex genomic information and provide clinical decision support.
• Faxing Support: Integration of faxing capabilities to streamline communication with healthcare providers and stakeholders.

This partnership underscores Adela’s commitment to leveraging innovative technologies to accelerate cancer diagnosis and improve patient outcomes.

About Adela

Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela’s genome-wide methylome enrichment platform efficiently captures extensive, biologically-relevant genomic information to maximize test performance and improve treatment decisions. The company’s approach to MRD testing is tissue-agnostic, eliminating the need for tumor samples.

About Dendi

Dendi is a leading provider of innovative laboratory information systems designed to streamline operations, enhance data accuracy, and improve patient outcomes. With a focus on flexibility and user-centric design, Dendi’s solutions cater to laboratories of all sizes, empowering them to meet the evolving demands of the healthcare industry.